Unlikely to cause harm — often a labeling or packaging issue.
Failed Impurities/Degradation Specifications; 18 month long term stability study.
| Brand name | TELMISARTAN AND AMLODIPINE |
| Generic name | TELMISARTAN AND AMLODIPINE |
| Active ingredient(s) | AMLODIPINE BESYLATE, TELMISARTAN |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, MD |
| NDC | 68180-198-06 |
| Full product label | Telmisartan and Amlodipine Tablets 80 mg/5 mg, 30 tablet bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by : Lupin Limited, Goa, INDIA -- NDC 68180-198-06 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed to 6 wholesalers/ drug chains and 2 mail order pharmacies that may have further distribute the product throughout the United States. |
| Quantity | 12,504 bottles |
| Recall initiated | 2019-04-01 |
| Report date | 2019-04-17 |
| Recall completed | 2020-07-01 |
| Recall number | D-1121-2019 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗